Parenkumar Patel
Internal Medicine · Wesley Chapel, FLNPI 1760613012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$930
- Novo Nordisk$910
- Boehringer Ingelheim$373
- Pfizer$330
- Lilly USA, LLC$278
- plus $1K from 26 others
Across 6 payments — averaging $43,671 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$261K
- Eli Lilly Export S.A. Puerto Rico Branch$2K
What the payments were for
- Food & beverage$5,416100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $1,289 |
| GSK | 49 | $930 |
| Novo Nordisk | 57 | $910 |
| Boehringer Ingelheim | 21 | $373 |
| Pfizer | 15 | $330 |
| Lilly USA, LLC | 13 | $278 |
| Bayer | 6 | $172 |
| Shield Therapeutics Inc | 8 | $154 |
| Johnson & Johnson | 7 | $139 |
| AbbVie | 5 | $106 |
| Myriad Women's Health, Inc. | 1 | $67 |
| Nevro Corp. | 3 | $59 |
| Currax Pharmaceuticals LLC | 4 | $58 |
| Hologic Sales And Service, LLC | 2 | $50 |
| Corcept Therapeutics | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $43 |
| Lucid Diagnostics Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Phadia US Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Amgen | 2 | $32 |
| Dexcom, Inc. | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Itamar Medical Inc | 1 | $28 |
| Renalytix AI, Inc. | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Recor Medical Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Abbott | 1 | $18 |
| Biogen | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Gilead | 1 | $15 |
How this compares
$5,416 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $41,142 |
| FarxigaDapagliflozin Propanediol | 44 | $38,835 |
| EliquisApixaban | 29 | $34,749 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $22,163 |
| XareltoRivaroxaban | 19 | $16,669 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $11,939 |
| MounjaroTirzepatide | 11 | $11,204 |
| Glipizide ErGlipizide | 400 | $6,885 |
| Losartan Potassium | 958 | $6,260 |
| Atorvastatin Calcium | 922 | $5,451 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $5,402 |
| Levothyroxine Sodium | 586 | $5,339 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $4,993 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $3,663 |
| Midodrine Hcl | 14 | $3,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $373 | $41,14232 claims |
| AstraZenecaFarxiga | $1,289 | $38,83544 claims |
| PfizerEliquis | $330 | $34,74929 claims |
| GSKTrelegy Ellipta | $930 | $22,16315 claims |
| Johnson & JohnsonXarelto | $139 | $16,66919 claims |
| Lilly USA, LLCMounjaro | $278 | $11,20411 claims |
| Sanofi-aventis U.S. LLCLantus | $36 | $1,73115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Wesley Chapel
- Manish ShahWesley Chapel$101K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.